Your browser doesn't support javascript.
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.
Fahrner, Jean-Eudes; Lahmar, Imran; Goubet, Anne-Gaëlle; Haddad, Yacine; Carrier, Agathe; Mazzenga, Marine; Drubay, Damien; Alves Costa Silva, Carolina; de Sousa, Eric; Thelemaque, Cassandra; Melenotte, Cléa; Dubuisson, Agathe; Geraud, Arthur; Ferrere, Gladys; Birebent, Roxanne; Bigenwald, Camille; Picard, Marion; Cerbone, Luigi; Lérias, Joana R; Laparra, Ariane; Bernard-Tessier, Alice; Kloeckner, Benoît; Gazzano, Marianne; Danlos, François-Xavier; Terrisse, Safae; Pizzato, Eugenie; Flament, Caroline; Ly, Pierre; Tartour, Eric; Benhamouda, Nadine; Meziani, Lydia; Ahmed-Belkacem, Abdelhakim; Miyara, Makoto; Gorochov, Guy; Barlesi, Fabrice; Trubert, Alexandre; Ungar, Benjamin; Estrada, Yeriel; Pradon, Caroline; Gallois, Emmanuelle; Pommeret, Fanny; Colomba, Emeline; Lavaud, Pernelle; Deloger, Marc; Droin, Nathalie; Deutsch, Eric; Gachot, Bertrand; Spano, Jean-Philippe; Merad, Mansouria; Scotté, Florian.
  • Fahrner JE; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Lahmar I; Gustave Roussy, Villejuif, France.
  • Goubet AG; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Haddad Y; Transgene S.A., Illkirch-Graffenstaden, France.
  • Carrier A; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Mazzenga M; Gustave Roussy, Villejuif, France.
  • Drubay D; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Alves Costa Silva C; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • de Sousa E; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Thelemaque C; Gustave Roussy, Villejuif, France.
  • Melenotte C; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Dubuisson A; Gustave Roussy, Villejuif, France.
  • Geraud A; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Ferrere G; Gustave Roussy, Villejuif, France.
  • Birebent R; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Bigenwald C; Gustave Roussy, Villejuif, France.
  • Picard M; Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Cerbone L; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Lérias JR; Gustave Roussy, Villejuif, France.
  • Laparra A; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Kloeckner B; ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal.
  • Gazzano M; Gustave Roussy, Villejuif, France.
  • Danlos FX; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Terrisse S; Gustave Roussy, Villejuif, France.
  • Pizzato E; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Flament C; Aix-Marseille Université, Institut Hospitalo-Universitaire, Institut de Recherche pour le Développement, Assistance Publique - Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille, France.
  • Ly P; Gustave Roussy, Villejuif, France.
  • Tartour E; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Benhamouda N; Gustave Roussy, Villejuif, France.
  • Meziani L; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
  • Ahmed-Belkacem A; Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.
  • Miyara M; Gustave Roussy, Villejuif, France.
  • Gorochov G; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Barlesi F; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Trubert A; Gustave Roussy, Villejuif, France.
  • Ungar B; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Estrada Y; Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.
  • Pradon C; Gustave Roussy, Villejuif, France.
  • Gallois E; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Pommeret F; Gustave Roussy, Villejuif, France.
  • Colomba E; Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
  • Lavaud P; Gustave Roussy, Villejuif, France.
  • Deloger M; Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.
  • Droin N; ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal.
  • Deutsch E; Gustave Roussy, Villejuif, France.
  • Gachot B; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
  • Spano JP; Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.
  • Merad M; Gustave Roussy, Villejuif, France.
  • Scotté F; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
Cancer Discov ; 12(4): 958-983, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-2108398
ABSTRACT
Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants.

SIGNIFICANCE:

This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 / Antiviral Restriction Factors / Neoplasms Type of study: Diagnostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Cancer Discov Year: 2022 Document Type: Article Affiliation country: 2159-8290.CD-21-1441

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 / Antiviral Restriction Factors / Neoplasms Type of study: Diagnostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Cancer Discov Year: 2022 Document Type: Article Affiliation country: 2159-8290.CD-21-1441